Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.
In August 2012, the Centers for Disease Control and Prevention, in partnership with the Association of Maternal and Child Health Programs, convened a meeting of national subject matter experts to review key clinical elements of anthrax prevention and treatment for pregnant, postpartum, and lactating (P/PP/L) women. National experts in infectious disease, obstetrics, maternal fetal medicine, neonatology, pediatrics, and pharmacy attended the meeting, as did representatives from professional organizations and national, federal, state, and local agencies. The meeting addressed general principles of prevention and treatment for P/PP/L women, vaccines, antimicrobial prophylaxis and treatment, clinical considerations and critical care issues, antitoxin, delivery concerns, infection control measures, and communication. The purpose of this meeting summary is to provide updated clinical information to health care providers and public health professionals caring for P/PP/L women in the setting of a bioterrorist event involving anthrax.
Dana
D
Meaney-Delman
Marianne E
ME
Zotti
Andreea A
AA
Creanga
Lara K
LK
Misegades
Etobssie
E
Wako
Tracee A
TA
Treadwell
Nancy E
NE
Messonnier
Denise J
DJ
Jamieson
D000328:Adult; D000881:Anthrax / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000992:Antitoxins / Q000627:therapeutic use; D001408:Bacillus anthracis / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity*; D023482:Bioterrorism; D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D005333:Fetus; D006801:Humans; D007223:Infant; D007774:Lactation; D049590:Postpartum Period; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D014481:United States
D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000992:Antitoxins; C542124:raxibacumab
Bacillus anthracis; PEP; anthrax; antibacterial agents; antibiotics; antimicrobial drugs; antitoxins; bacteria; breast-feeding; lactation; postexposure prophylaxis; postpartum period; pregnancy; treatment; vaccination; vaccine; women